The Maxillo-Facial Surgery Department, Baruch Padeh Medical Center, The Faculty of Medicine, Bar Ilan University, Galilee, Israel.
Department of Urology, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
Arch Oral Biol. 2018 Nov;95:141-148. doi: 10.1016/j.archoralbio.2018.07.018. Epub 2018 Aug 6.
Recurrent and metastatic Oral Squamous Cell Carcinoma (OSCC) is often incurable. There are large gaps in the understanding of the clinical course, biology and genetic biomarkers of OSCC which could help us identify patients with high-risk of recurrence who may benefit from intensified therapy or novel targeted therapy trials. The purpose of this study was to identify significant clinical, pathological and genomic risk factors for local recurrence in OSCC.
Molecular data sets and clinicopathological characteristics of 159 head and neck carcinoma patients were obtained from The Cancer Genome Atlas (TCGA) data portal and analyzed using the Genome Data Analysis Center and cBioPortal to find significant risk factors for tumor recurrence.
The local recurrence rate was 24%. OSCC originating from the buccal mucosa composed 13% of all the tumors in the recurrent group, making it a statistically significant risk of recurrence (P value = 0.03). Likewise, positive surgical margins, pathological T staging, and alcohol consumption were found to be significantly associated with recurrence (P value < 0.05). Genetic profiling revealed the top 5 mutated genes (using the MutSigCV analysis). Only one of these genes, CASP8 was the only gene that was significantly altered only in the recurrent group (Q value = 8.7 × 10). The fingerprint of 5 mutated genes was found in 97% of the patients in the recurrence group. Moreover, copy number alterations in cytoband 5p15.33, which involved amplification in telomerase reverse-transcriptase (TERT) gene, was found to be significant only in the recurrent group.
In the current study, we found several clinical and genetic characteristics that could define patients with high-risk of OSCC recurrence. This provides a means of identifying patients that may benefit from intensified therapy or novel targeted therapy trials.
复发性和转移性口腔鳞状细胞癌(OSCC)通常无法治愈。目前,我们对 OSCC 的临床病程、生物学和遗传生物标志物的了解还存在很大差距,这些知识可能有助于我们识别出具有高复发风险的患者,他们可能受益于强化治疗或新的靶向治疗试验。本研究的目的是确定 OSCC 局部复发的显著临床、病理和基因组危险因素。
从癌症基因组图谱(TCGA)数据门户获取 159 例头颈部癌患者的分子数据集和临床病理特征,并使用基因组数据分析中心和 cBioPortal 进行分析,以寻找肿瘤复发的显著危险因素。
局部复发率为 24%。在复发性肿瘤组中,起源于颊黏膜的 OSCC 占所有肿瘤的 13%,这是一个具有统计学意义的复发风险(P 值=0.03)。同样,阳性手术切缘、病理 T 分期和饮酒也与复发显著相关(P 值<0.05)。遗传分析显示前 5 个突变基因(使用 MutSigCV 分析)。只有一个基因 CASP8 在复发性肿瘤组中发生了显著改变(Q 值=8.7×10)。这 5 个突变基因的指纹图谱在复发性肿瘤组的 97%的患者中都存在。此外,在涉及端粒酶逆转录酶(TERT)基因扩增的 5p15.33 细胞带中发现的拷贝数改变仅在复发性肿瘤组中具有显著意义。
在本研究中,我们发现了一些临床和遗传特征,可以定义具有高 OSCC 复发风险的患者。这为识别可能受益于强化治疗或新的靶向治疗试验的患者提供了一种方法。